<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Champions Oncology


Recent Posts

Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates

Jan 20, 2022 8:50:46 AM / by Champions Oncology

Hackensack, NJ – January 20, 2022 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio. The partnership will combine novel therapeutic targets identified within Champions’ Lumin platform with Fannin’s Therapeutic Raptamer platform to develop next generation Raptamer Drug Conjugates (RDC’s). RDCs engage tumor-specific therapeutic targets at a cell’s surface to deliver potent toxic payloads to the tumor, without affecting normal cells. The planned partnership will initiate with a single program focused on a previously unexplored target present in tumor indications such as non-small cell lung cancer (NSCLC), head and neck cancer, and other solid tumors. The partnership will also leverage the unique experimental platforms available at Champions to ensure rapid and efficient development towards clinical evaluation. Under the terms of this agreement, Champions and Fannin will share equal ownership of the developed therapeutic and establish a joint venture after specific development milestones are met.

Read More →

Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs

Jan 4, 2022 9:17:36 AM / by Champions Oncology

Hackensack, NJ – January 4, 2022 Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Alloy's fully-integrated in vivo and in vitro antibody discovery, optimization, and lead development services platform to develop antibodies used in the development of next generation Antibody Drug Conjugates (ADCs).

Read More →

Champions Oncology Reports Quarterly Revenue of $11.8 Million

Dec 15, 2021 8:23:52 AM / by Champions Oncology

Hackensack, NJ - December 13, 2021 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, today announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021.

Read More →

Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus

Oct 20, 2021 10:23:23 AM / by Champions Oncology

Hackensack, NJ – October 20, 2021 – Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan.

After launching preclinical and clinical GCLP-compliant biomarker services in 2019, Champions Oncology has rapidly grown to be a leader in the industry by providing scientific expertise, unparalleled quality, and innovative data analytics.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

Sep 14, 2021 2:33:55 PM / by Champions Oncology

Hackensack, NJ – September 13, 2021Champions Oncology, Inc. (Nasdaq: CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.

First Quarter and Recent Highlights: 

  • Record quarterly revenue of $11.3 million, an increase of 18% year over year
  • Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000
  • Validated 6 therapeutic discovery targets

Read More →